EP300 silencing is also associated with increased in vitro tumorigenicity and CSC-like markers, whilst its ectopic expression in basal-like breast cancer cells partly rescues the epithelial, differentiated and paclitaxel-sensitive phenotype. Here, EP300 is linked to breast carcinoma.